CME Group Inc.
NASDAQ:CMEFinancial - Data & Stock Exchanges
-$6.03 today
- Market cap
- $111.05B
- Beta
- 0.24
- P/E (TTM)
- 20.9
- EPS (TTM)
- $11.81
- Dividend yield
- 4.56%
Volume 2.01M
Average 2.82M
CME Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
CME Group Inc.NASDAQ: CME
Cost of Revenue · Q3 FY2026 · quarter ended Sep 2026
Cost of revenue dips below year-ago levels
Q3 FY2026 cost of revenue of $104.2M fell 56.1% year over year, behind the +23.3% change in trailing-twelve-month cost of revenue. Sequentially, it fell 80.1% from the prior quarter. Over 3 fiscal years it compounded at +6.4% a year.
Context
- Cost of revenue amounted to 13.9% of revenue in FY2025, unchanged from a year earlier.
- Cost of revenue increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -56.1% toward the trailing-twelve-month pace of +23.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 907M USD
- Year-over-year change
- +6.7%
- 4-year CAGR
- +2.0%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 907M | +6.7% |
| FY2024 | 2024-12-31 | 850.3M | +2.6% |
| FY2023 | 2023-12-31 | 828.6M | +10.0% |
| FY2022 | 2022-12-31 | 753.1M | -10.0% |
| FY2021 | 2021-12-31 | 837M | — |
Cost of Revenue vs competitors
How CME compares with its peers on the latest reported figures
- CME's LTM Sep 2026 cost of revenue of $1.09B is the 3rd highest of the 4 companies compared; the peer median is $2.62B.
- Its year-over-year change of +23.3% is the highest of 4, against a peer median of -30.1%.
- Cost of revenue amounts to 15.7% of revenue for CME, versus a peer median of 31.9%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Sep 2026 | $3.36B | -30.1% | +3.3% | 36.8% | |
| LTM Jun 2026 | $2.62B | -53.8% | +2.8% | 21.0% | |
| LTM Sep 2026 | $1.09B | +23.3% | +6.4% | 15.7% | |
| LTM Jun 2026 | $702.89M | +6.7% | +15.8% | 31.9% | |
| Peer median (excluding CME) | $2.62B | -30.1% | +3.3% | 31.9% | |
Competitors are the stored peer set for CME. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 4.69B | 5.02B | 5.58B | 6.13B | 6.52B |
| Cost of Revenue | 837M | 753.1M | 828.6M | 850.3M | 907M |
| Gross Profit | 3.85B | 4.27B | 4.75B | 5.28B | 5.61B |
| Gross Margin | 82.2% | 85.0% | 85.1% | 86.1% | 86.1% |
| Research & Development | 0 | 0 | 0 | 0 | 0 |
| Selling, General & Admin | 151.7M | 137.4M | 144.4M | 132.7M | 150.5M |
| Operating Expenses | 1.21B | 1.25B | 1.31B | 1.35B | 1.38B |
| Depreciation & Amortization | 385.4M | 362.6M | 352.6M | 336.8M | 330.9M |
| EBITDA | 3.93B | 4.02B | 4.67B | 5.04B | 5.78B |
| EBITDA Margin | 83.7% | 80.0% | 83.6% | 82.2% | 88.6% |
| Operating Income | 2.65B | 3.02B | 3.44B | 3.93B | 4.23B |
| Operating Margin | 56.4% | 60.1% | 61.6% | 64.1% | 64.9% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 166.9M | 162.7M | 159.4M | 160.9M | 129.7M |
| Other Income / Expenses | 728.4M | 474.4M | 717.9M | 609.9M | 1.1B |
| Income Before Tax | 3.37B | 3.49B | 4.15B | 4.54B | 5.33B |
| Pre-Tax Margin | 71.9% | 69.5% | 74.5% | 74.1% | 81.7% |
| Income Tax Expense | 736.7M | 799.3M | 927.4M | 1.02B | 1.27B |
| Net Income | 2.64B | 2.69B | 3.23B | 3.53B | 4.04B |
| Net Margin | 56.2% | 53.6% | 57.8% | 57.5% | 62.0% |
| EPS (Basic) | 7.30 | 7.41 | 8.87 | 9.69 | 11.18 |
| EPS (Diluted) | 7.29 | 7.40 | 8.86 | 9.67 | 11.16 |
| Weighted Avg Shares | 358.34M | 358.71M | 359.02M | 359.39M | 359.63M |
| Weighted Avg Shares (Diluted) | 358.93M | 359.18M | 359.5M | 359.94M | 360.23M |
CME Group Inc.
NASDAQ:CME
Intrinsic Alpha fair value
Locked
Current Price
$310.25
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.